Posterior vitreous detachment rate following intravitreal dexamethasone injection
Author:
Corresponding Author:

Atilla Alpay. Zonguldak Bülent Ecevit üniversitesi Tip Fakültesi, G?z Hastaliklari Anabilim Dali, Kozlu, Zonguldak 67600, Turkey. atillaalpay@hotmail.com

  • Article
  • | |
  • Metrics
  • |
  • Reference [38]
  • |
  • Related [20]
  • | | |
  • Comments
    Abstract:

    AIM: To determine whether intravitreal dexamethasone (DEX) implant induces posterior vitreous detachment or not. METHODS: We retrospectively reviewed 810 eyes of 405 patients who underwent intravitreal DEX implantation due to macular edema caused by diabetic and retinal venous occlusion in our clinic. The eyes having no injection were determined as the control group. The examination findings of the patients before the injection and 3mo after the injection and optical coherence tomography (OCT) images were scanned. The pre-injection OCT findings and OCT findings of the patients having no posterior vitreous detachment (PVD) and determined to have partial PVD were compared. RESULTS: The separation in vitreoretinal adhesion and total PVD development of DEX-injected 56/208 (26.9%) eyes were statistically greater in comparison with the 12/129 (9.3%) eyes that had not been injected (P=0.001). PVD development was observed more in the patients that were younger, had larger macula thickness and lower visual acuity. CONCLUSION: It can be stated that intravitreal DEX implant induces PVD development. Prospective, controlled studies are required in order to determine prognosis of vitreoretinal disease in PVD-developed patients and in non-PVD-developed patients.

    Reference
    1 Sebag J. Anatomy and pathology of the vitreo-retinal interface. Eye (Lond) 1992;6(Pt 6):541-552.
    2 Johnson MW. Perifoveal vitreous detachment and its macular complications. Trans Am Ophthalmol Soc 2005;103:537-567.
    3 Simpson AR, Petrarca R, Jackson TL. Vitreomacular adhesion and neovascular age-related macular degeneration. Surv Ophthalmol 2012;57(6):498-509.
    4 Uchino E, Uemura A, Ohba N. Initial stages of posterior vitreous detachment in healthy eyes of older persons evaluated by optical coherence tomography. Arch Ophthalmol 2001;119(10):1475-1479.
    5 Holekamp NM. Vitreomacular adhesion in active and end-stage age-related macular degeneration. Am J Ophthalmol 2010;149(1):171-172; author reply 172-173.
    6 Steel DH, Lotery AJ. Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treatment. Eye (Lond) 2013;27(Suppl 1):S1-21.
    7 Shechtman DL, Dunbar MT. The expanding spectrum of vitreomacular traction. Optometry 2009;80(12):681-687.
    8 Jackson TL, Nicod E, Simpson A, Angelis A, Grimaccia F, Kanavos P. Symptomatic vitreomacular adhesion. Retina 2013;33(8):1503-1511.
    9 Nasrallah FP, Jalkh AE, Van Coppenolle F, Kado M, Trempe CL, McMeel JW, Schepens CL. The role of the vitreous in diabetic macular edema. Ophthalmology 1988;95(10):1335-1339.
    10 Jackson TL, Nicod E, Angelis A, Grimaccia F, Prevost AT, Simpson AR, Kanavos P. Vitreous attachment in age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: a systematic review and metaanalysis. Retina 2013;33(6):1099-1108.
    11 Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014;121(1):150-161.
    12 Mojana F, Cheng L, Bartsch DU, Silva GA, Kozak I, Nigam N, Freeman WR. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol 2008;146(2):218-227.
    13 Arai M, Yamamoto S, Mitamura Y, Sato E, Sugawara T, Mizunoya S. Efficacy of vitrectomy and internal limiting membrane removal for macular edema associated with branch retinal vein occlusion. Ophthalmologica 2009;223(3):172-176.
    14 Diabetic Retinopathy Clinical Research Network Writing Committee, Haller JA, Qin H, et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 2010;117(6): 1087-1093.e3.
    15 Shaikh M, Miller JB, Papakostas TD, Husain D. The efficacy and safety profile of ocriplasmin in vitreomacular interface disorders. Semin Ophthalmol 2017;32(1):52-55.
    16 Varma R, Haller JA, Kaiser PK. Improvement in patient-reported visual function after ocriplasmin for vitreomacular adhesion: results of the microplasmin for intravitreous injection-traction release without surgical treatment (MIVI-TRUST) trials. JAMA Ophthalmol 2015;133(9):997-1004.
    17 Dugel PU, Tolentino M, Feiner L, Kozma P, Leroy A. Results of the 2-year ocriplasmin for treatment for symptomatic vitreomacular adhesion including macular hole (OASIS) randomized trial. Ophthalmology 2016;123(10):2232-2247.
    18 Geck U, Pustolla N, Baraki H, Atili A, Feltgen N, Hoerauf H. Posterior vitreous detachment following intravitreal drug injection. Graefes Arch Clin Exp Ophthalmol 2013;251(7):1691-1695.
    19 Alagöz N, Alagöz C, Yılmaz I, Yıldırım Y, Baz Ö, Altan Ç, Yazıcı AT, Taşkapılı M. Immediate intraocular pressure changes following intravitreal dexamethasone implant. J Ocul Pharmacol Ther 2016;32(1):44-49.
    20 Xu L, Li Y, Wang S, Wang Y, Wang Y, Jonas JB. Characteristics of highly myopic eyes: the Beijing Eye Study. Ophthalmology 2007;114(1): 121-126.
    21 McKibbin MA, Suter CA, Willis TA. The influence of vitreomacular adhesion on outcomes after aflibercept therapy for neovascular age-related macular degeneration. Retina 2015;35(10):1951-1956.
    22 Kulikov AN, Sosnovskii SV, Berezin RD, Maltsev DS, Oskanov DH, Gribanov NA. Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study. Clin Ophthalmol 2017;11:1995-2002.
    23 Sebag J. Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch Clin Exp Ophthalmol 2004;242(8):690-698.
    24 Lopes de Faria JM, Jalkh AE, Trempe CL, McMeel JW. Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol Scand 1999;77(2):170-175.
    25 Schubert HD. Cystoid macular edema: the apparent role of mechanical factors. Prog Clin Biol Res 1989;312:277-291.
    26 Dogru M, Inoue M, Nakamura M, Yamamoto M. Modifying factors related to asymmetric diabetic retinopathy. Eye (Lond) 1998;12(Pt 6): 929-933.
    27 Weber-Krause B, Eckardt U. Incidence of posterior vitreous detachment in eyes with and without age-related macular degeneration. An ultrasonic study. Ophthalmologe 1996;93(6):660-665.
    28 Foos RY, Kreiger AE, Forsythe AB, Zakka KA. Posterior vitreous detachment in diabetic subjects. Ophthalmology 1980;87(2):122-128.
    29 Tagawa H, McMeel JW, Furukawa H, Quiroz H, Murakami K, Takahashi M, Trempe CL. Role of the vitreous in diabetic retinopathy. I. Vitreous changes in diabetic retinopathy and in physiologic aging. Ophthalmology 1986;93(5):596-601.
    30 Meyer CH, Michels S, Rodrigues EB, Hager A, Mennel S, Schmidt JC, Helb HM, Farah ME. Incidence of rhegmatogenous retinal detachments after intravitreal antivascular endothelial factor injections. Acta Ophthalmol 2011;89(1):70-75.
    31 Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 2013;27(7):787-794.
    32 Schneider EW, Johnson MW. Emerging nonsurgical methods for the treatment of vitreomacular adhesion: a review. Clin Ophthalmol 2011;5:1151-1165.
    33 Zola M, Briamonte C, Lorenzi U, Machetta F, Grignolo FM, Fea AM. Treatment of refractory uveitic macular edema: results of a first and second implant of long-acting intravitreal dexamethasone. Clin Ophthalmol 2017;11:1949-1956.
    34 Winterhalter S, Eckert A, Vom Brocke GA, Schneider A, Pohlmann D, Pilger D, Joussen AM, Rehak M, Grittner U. Real-life clinical data for dexamethasone and ranibizumab in the treatment of branch or central retinal vein occlusion over a period of six months. Graefes Arch Clin Exp Ophthalmol 2018;256(2):267-279.
    35 Bonfiglio V, Reibaldi M, Fallico M, Russo A, Pizzo A, Fichera S, Rapisarda C, Macchi I, Avitabile T, Longo A. Widening use of dexamethasone implant for the treatment of macular edema. Drug Des Devel Ther 2017;11:2359-2372.
    36 Gella L, Raman R, Pal SS, Ganesan S, Sharma T. Incidence, progression, and associated risk factors of posterior vitreous detachment in type 2 diabetes mellitus: sankara nethralaya diabetic retinopathy epidemiology and molecular genetic study (SN-DREAMS II, report No. 7). Semin Ophthalmol 2017;32(2):191-197.
    37 Chuo JY, Lee TY, Hollands H, Morris AH, Reyes RC, Rossiter JD, Meredith SP, Maberley DA. Risk factors for posterior vitreous detachment: a case-control study. Am J Ophthalmol 2006;142(6):931-937.
    38 Bertelmann T, Goos C, Sekundo W, Schulze S, Mennel S. Is optical coherence tomography a useful tool to objectively detect actual posterior vitreous adhesion status? Case Rep Ophthalmol Med 2016;2016:3953147.
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Atilla Alpay. Posterior vitreous detachment rate following intravitreal dexamethasone injection. Int J Ophthalmol, 2019,12(8):1298-1303

Copy
Share
Article Metrics
  • Abstract:947
  • PDF: 594
  • HTML: 300
  • Cited by: 0
Publication History
  • Received:August 24,2018
  • Revised:March 12,2019
  • Online: July 09,2019